ABL Diagnostics Société anonyme (EPA:ABLD)

France flag France · Delayed Price · Currency is EUR
2.840
+0.040 (1.43%)
Apr 2, 2026, 4:12 PM CET
Market Cap45.76M -43.8%
Revenue (ttm)6.23M +0.4%
Net Income463.36K +150.9%
EPSn/a
Shares Out16.11M
PE Ratio98.76
Forward PEn/a
Dividend0.05 (1.76%)
Ex-Dividend Daten/a
Volume135
Average Volume5,286
Open2.800
Previous Close2.800
Day's Range2.800 - 2.840
52-Week Range2.620 - 5.750
Beta-0.55
RSI39.92
Earnings DateMay 13, 2026

About EPA:ABLD

ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S RNA; ultragene assays for viral detection of SARS CoV-2, MonkeyPox, and Clostridium; microbiological specimen transport and collection kits, which inc... [Read more]

Sector Healthcare
CEO Chalom Sayada
Employees 19
Stock Exchange Euronext Paris
Ticker Symbol ABLD
Full Company Profile

Financial Performance

In 2024, EPA:ABLD's revenue was 5.87 million, a decrease of -5.16% compared to the previous year's 6.19 million. Earnings were 285,170, an increase of 424.58%.

Financial Statements